New therapies in non-Hodgkin lymphoma

被引：6

作者：

Novelli, Silvana ^{[1
]}

Sierra, Jorge ^{[1
]}

Briones, Javier ^{[1
]}

机构：

[1] Hosp Santa Creu & Sant Pau, Hematol Serv, Barcelona 08041, Spain

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2015年 / 15卷 / 03期

关键词：

antibodies; B cell receptor; lymphoma; NF-B inhibitors; non-Hodgkin lymphoma; treatment; MANTLE-CELL LYMPHOMA; PHASE-II TRIAL; CHRONIC LYMPHOCYTIC-LEUKEMIA; SINGLE-AGENT LENALIDOMIDE; C-BETA INHIBITOR; NF-KAPPA-B; OPEN-LABEL; FOLLICULAR LYMPHOMA; OFATUMUMAB MONOTHERAPY; 1ST-LINE TREATMENT;

D O I：

10.1586/14737140.2015.1002773

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Non-Hodgkin lymphomas are among the most prevalent hematologic malignancies. Although the addition of rituximab (R) to chemotherapy has made a big impact in the treatment of B cell lymphomas, most of them are not cured yet. The panorama in natural killer/T cell lymphomas is more unsatisfactory, thus representing a group of diseases where effective therapies constitute an urgent medical need. In recent years, several new antineoplastic agents have been tested in clinical trials showing promising results. The aim of this review is to update information of these studies that are already changing the scenario of the treatment of patients with Non-Hodgkin lymphoma.

引用

页码：349 / 359

页数：11

共 73 条

[1] The development of proteasome inhibitors as anticancer drugs [J].

Adams, J .

CANCER CELL, 2004, 5 (05) :417-421

[2] Combined Lenalidomide, Low-Dose Dexamethasone, and Rituximab Achieves Durable Responses in Rituximab-Resistant Indolent and Mantle Cell Lymphomas [J].

Ahmadi, Tahamtan ;

Chong, Elise A. ;

Gordon, Amanda ;

Aqui, Nicole A. ;

Nasta, Sunita D. ;

Svoboda, Jakub ;

Mato, Anthony R. ;

Schuster, Stephen J. .

CANCER, 2014, 120 (02) :222-228

[3] Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies [J].

Alduaij, Waleed ;

Ivanov, Andrei ;

Honeychurch, Jamie ;

Cheadle, Eleanor J. ;

Potluri, Sandeep ;

Lim, Sean H. ;

Shimada, Kazuyuki ;

Chan, Claude H. T. ;

Tutt, Alison ;

Beers, Stephen A. ;

Glennie, Martin J. ;

Cragg, Mark S. ;

Illidge, Tim M. .

BLOOD, 2011, 117 (17) :4519-4529

[4]

[Anonymous], 2014, CLIN ADV HEMATOL ONC, V12, P12

[5]

[Anonymous], J CLIN ONCOL S

[6] Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma - A phase 2 trial in the North Central Cancer Treatment Group [J].

Ansell, Stephen M. ;

Inwards, David J. ;

Rowland, Kendrith M., Jr. ;

Flynn, Patrick J. ;

Morton, Roscoe F. ;

Moore, Dennis F., Jr. ;

Kaufmann, Scott H. ;

Ghobrial, Irene ;

Kurtin, Paul J. ;

Maurer, Matthew ;

Allmer, Christine ;

Witzig, Thomas E. .

CANCER, 2008, 113 (03) :508-514

[7] Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study [J].

Ansell, Stephen M. ;

Tang, Hui ;

Kurtin, Paul J. ;

Koenig, Patricia A. ;

Inwards, David J. ;

Shah, Keith ;

Ziesmer, Steven C. ;

Feldman, Andrew L. ;

Rao, Radha ;

Gupta, Mamta ;

Erlichman, Charles ;

Witzig, Thomas E. .

LANCET ONCOLOGY, 2011, 12 (04) :361-368

[8] Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial [J].

Armand, Philippe ;

Nagler, Arnon ;

Weller, Edie A. ;

Devine, Steven M. ;

Avigan, David E. ;

Chen, Yi-Bin ;

Kaminski, Mark S. ;

Holland, H. Kent ;

Winter, Jane N. ;

Mason, James R. ;

Fay, Joseph W. ;

Rizzieri, David A. ;

Hosing, Chitra M. ;

Ball, Edward D. ;

Uberti, Joseph P. ;

Lazarus, Hillard M. ;

Mapara, Markus Y. ;

Gregory, Stephanie A. ;

Timmerman, John M. ;

Andorsky, David ;

Or, Reuven ;

Waller, Edmund K. ;

Rotem-Yehudar, Rinat ;

Gordon, Leo I. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (33) :4199-4206

[9] A Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results In Patients With DLBCL and Other B-Cell Lymphomas [J].

Bartlett, Nancy L. ;

Sharman, Jeff P. ;

Oki, Yasuhiro ;

Advani, Ranjana H. ;

Bello, Celeste M. ;

Winter, Jane N. ;

Yang, Yin ;

Kennedy, Dana A. ;

Jacobsen, Eric D. .

BLOOD, 2013, 122 (21)

[10] Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies [J].

Berger, Raanan ;

Rotem-Yehudar, Rinat ;

Slama, Gideon ;

Landes, Shimon ;

Kneller, Abraham ;

Leiba, Merav ;

Koren-Michowitz, Maya ;

Shimoni, Avichai ;

Nagler, Arnon .

CLINICAL CANCER RESEARCH, 2008, 14 (10) :3044-3051

← 1 2 3 4 5 6 7 8 →